Cultural advice

The Australian National University acknowledges, celebrates and pays our respects to the Ngunnawal and Ngambri people of the Canberra region and to all First Nations Australians on whose traditional lands we meet and work, and whose cultures are among the oldest continuing cultures in human history.

Aboriginal and Torres Strait Islander peoples are advised that ANU Library collections may include images, names, voices, and other representations of deceased persons.

Material in the collection may contain terms, language or views that reflect the period in which the item was created and may be considered inappropriate today.

The use of the vaccinia virus complement control protein (VCP) in the rat retina

dc.contributor.authorFernando, Nilisha
dc.contributor.authorNatoli, Riccardo
dc.contributor.authorRacic, Tanja
dc.contributor.authorWooff, Yvette
dc.contributor.authorProvis, Jan
dc.contributor.authorValter, Krisztina
dc.date.accessioned2019-04-08T12:02:34Z
dc.date.available2019-04-08T12:02:34Z
dc.date.issued2018
dc.date.updated2019-03-12T07:21:58Z
dc.description.abstractThe complement system is highly implicated in both the prevalence and progression of Age-Related Macular Degeneration (AMD). Complement system inhibitors therefore have potential therapeutic value in managing excessive activation of the complement pathways in retinal degenerations. The vaccinia virus complement control protein (VCP) has been shown to be effective as a complement inhibitor in neuroinflammatory models including traumatic brain injury and spinal cord injury. We aimed to investigate the potential of VCP as a therapeutic molecule for retinal degenerations. In this study, we investigated the effect, localisation and delivery of VCP to the rodent retina. Complement inhibition activity of VCP was tested using a hemolytic assay. Photoreceptor cell death, inflammation and retinal stress were assayed to determine if any retinal toxicity was induced by an intravitreal injection of VCP. The effect of VCP was investigated in a model of photo-oxidative retinal degeneration. Localisation of VCP after injection was determined using a fluorescein-tagged form of VCP, as well as immunohistochemistry. Finally, a copolymer resin (Elvax) was trialled for the slow-release delivery of VCP to the retina. We found that a dose equivalent to 20|jg VCP when intravitreally injected into the rat eye did not cause any photoreceptor cell death or immune cell recruitment, but led to an increase in GFAP. In photo-oxidative damaged retinas, there were no differences in photoreceptor loss, retinal stress (Gfap) and inflammation (Ccl2 and C3) between VCP and saline-injected groups; however, Jun expression was reduced in VCP-treated retinas. After VCP was injected into the eye, it was taken up in all layers of the retina but was cleared within 1-3 hours of delivery. This study indicates that a method to sustain the delivery of VCP to the retina is necessary to further investigate the effect of VCP as a complement inhibitor for retinal degenerationsen_AU
dc.format.mimetypeapplication/pdfen_AU
dc.identifier.issn1932-6203en_AU
dc.identifier.urihttp://hdl.handle.net/1885/159346
dc.language.isoen_AUen_AU
dc.provenanceJournal: PLoS ONE [1] (ESSN: 1932-6203) RoMEO: This is a RoMEO green journal Listed in: DOAJ as an open access journal Author's Pre-print: green tick author can archive pre-print (ie pre-refereeing) Author's Post-print: green tick author can archive post-print (ie final draft post-refereeing) Publisher's Version/PDF: green tick author can archive publisher's version/PDFen_AU
dc.publisherPublic Library of Scienceen_AU
dc.rightsAuthors retain copyrighten_AU
dc.rights.licenseCreative Commons Attribution License 4.0
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.sourcePLOS ONE (Public Library of Science)en_AU
dc.titleThe use of the vaccinia virus complement control protein (VCP) in the rat retinaen_AU
dc.typeJournal articleen_AU
dcterms.accessRightsOpen Accessen_AU
local.bibliographicCitation.issue3en_AU
local.contributor.affiliationFernando, Nilisha, College of Health and Medicine, ANUen_AU
local.contributor.affiliationNatoli, Riccardo, College of Health and Medicine, ANUen_AU
local.contributor.affiliationRacic, Tanja, College of Health and Medicine, ANUen_AU
local.contributor.affiliationWooff, Yvette, College of Health and Medicine, ANUen_AU
local.contributor.affiliationProvis, Jan, College of Health and Medicine, ANUen_AU
local.contributor.affiliationValter, Krisztina, College of Health and Medicine, ANUen_AU
local.contributor.authoruidFernando, Nilisha, u4672578en_AU
local.contributor.authoruidNatoli, Riccardo, u4100537en_AU
local.contributor.authoruidRacic, Tanja, u4842896en_AU
local.contributor.authoruidWooff, Yvette, u5978390en_AU
local.contributor.authoruidProvis, Jan, u4118802en_AU
local.contributor.authoruidValter, Krisztina, u4055998en_AU
local.description.notesImported from ARIESen_AU
local.identifier.absfor110906 - Sensory Systemsen_AU
local.identifier.absseo920107 - Hearing, Vision, Speech and Their Disordersen_AU
local.identifier.ariespublicationa383154xPUB9567en_AU
local.identifier.citationvolume13en_AU
local.identifier.doi10.1371/journal.pone.0193740en_AU
local.identifier.scopusID2-s2.0-85043793367
local.type.statusPublished Versionen_AU

Downloads

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
01_Fernando_The_use_of_the_vaccinia_virus_2018.pdf
Size:
7.66 MB
Format:
Adobe Portable Document Format